Using subcutaneous tumor xenografts, knockdown of MRPS7 and MRPS23 dramatically potentiated cisplatin efficacy, leading to substantial decreases in both tumor volume and mass in cisplatin-administered murine models. The gene discussed is MRPS23; the disease is neoplasm.